Genomic Tests For Warfarin Could Gain Coverage With Study Participation
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a CMS proposal, genomic testing to predict warfarin response would receive Medicare coverage in the context of a clinical trial comparing the frequency of five kinds of adverse events with and without the tests.